<DOC>
	<DOC>NCT02767765</DOC>
	<brief_summary>This study will evaluate the efficacy and tolerability of subcutaneous (SC) or intramuscular (IM) recombinant human erythropoietin beta (r-HuEPO) in participants with anemia and histologically or cytologically confirmed cancer.</brief_summary>
	<brief_title>A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Histological or cytological confirmed cancer Participants who are treated with at least first line chemotherapy Hemoglobin less than (&lt;) 11 grams per deciliter (g/dL) Participants able to receive iron supplement, if necessary History of hypersensitivity to active or inactive excipients of rHuEPO Insufficient controllable hypertension Thalassemic syndromes Anemia caused by hematic loss Women who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>